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Abstract: The management of brain-dead organ donors is complex. The use of inotropic 
agents and replacement of depleted hormones (hormonal replacement therapy) is crucial for 
successful multiple organ procurement, yet the optimal hormonal replacement has not been 
identified, and the statistical adjustment to determine the best selection is not trivial. Traditional 
pair-wise comparisons between every pair of treatments, and multiple comparisons to all (MCA), 
are statistically conservative. Hsu’s multiple comparisons with the best (MCB) – adapted from 
the Dunnett’s multiple comparisons with control (MCC) – has been used for selecting the best 
treatment based on continuous variables. We selected the best hormonal replacement modality 
for successful multiple organ procurement using a two-step approach. First, we estimated the 
predicted margins by constructing generalized linear models (GLM) or generalized linear mixed 
models (GLMM), and then we applied the multiple comparison methods to identify the best 
hormonal replacement modality given that the testing of hormonal replacement modalities is 
independent. Based on 10-year data from the United Network for Organ Sharing (UNOS), among 
16 hormonal replacement modalities, and using the 95% simultaneous confidence intervals, 
we found that the combination of thyroid hormone, a corticosteroid, antidiuretic hormone, and 
insulin was the best modality for multiple organ procurement for transplantation.
Keywords: best treatment selection, brain-dead organ donors, hormonal replacement, multiple 
binary endpoints, organ procurement, multiple comparisons
Introduction
The inadequate supply and quality of organs that become available from deceased 
humans remain major hurdles for successful organ transplantation. After brain death, 
hormonal alterations may result in hemodynamic instability after brain death. The use 
of inotropic agents and replacement of depleted hormones (hormonal replacement 
therapy) have helped preserve satisfactory organ function. Currently, hormonal therapy 
can include the administration of four hormones – thyroid hormone (triiodothyronine 
[T3] or levothyroxine [T4]), a corticosteroid (eg, methylprednisolone), and/or antidi-
uretic hormone (arginine vasopressin or DDAVP), and/or insulin, each of which can 
be administered alone or in various combinations.1–7
Although there are reports demonstrating that combination hormonal therapy can sig-
nificantly increase the number of organs that can be procured from each brain-dead poten-
tial donor, the optimal regimen that maximizes multiple organ procurement and improves 
organ quality remains uncertain. In the present study, using data from the United Network 
for Organ Sharing (UNOS), we explored the optimal regimen from all possible combina-
tions of the four hormones, which proved a statistically challenging exercise.
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Table 1 hormonal replacement modalities
Group A (with T3/T4) Group B (without T3/T4)
Groups Treatment BDOD Groups Treatment BDOD
A1 t3/t4 + C + Adh + I 10,669 B1 C + Adh + I 3,553
A2 t3/t4 + C + Adh 2,935 B2 C + Adh 3,655
A3 t3/t4 + Adh + I 1,363 B3 Adh + I 985
A4 t3/t4 + Adh 1,118 B4 Adh 1,328
A5 t3/t4 + C + I 4,003 B5 C + I 2,158
A6 t3/t4 + C 1,545 B6 C 3,028
A7 t3/t4 + I 580 B7 I 791
A8 t3/t4 809 B8 None 1,604
Abbreviations: Adh, antidiuretic hormone (ddAVP or arginine vasopressin); Bdod, brain-dead organ donors; C, corticosteroid; I, insulin; t3/t4 = thyroid hormone 
(triiodothyronine [t3] or levothyroxine [t4]).
Statistically, to select the best modality from the many 
available hormonal replacement regimens is a multiple com-
parison problem. Traditional pair-wise comparison (multiple 
comparisons to all [MCA]) between every pair of treatments 
is statistically conservative. Hsu and others proposed a mul-
tiple comparison method to select the optimal treatment, 
known as multiple comparisons with the best (MCB), which 
was adapted from Dunnett’s multiple comparison with control 
(MCC) method by comparing each treatment with the best 
of the other treatments.8–12 Since it was developed, the MCB 
has been widely used to select the best treatment based on 
continuous endpoints. However, sometimes one needs to 
select the best treatment based on multiple endpoints, which 
usually are not continuous. In this report, we used a two-step 
method to select the best hormonal replacement modality 
based on six binary endpoints.
Materials and methods
data on potential organ donors
The data analyzed were provided by UNOS (Richmond, VA, 
USA). A total of 71,571 potential organ donors were regis-
tered at UNOS during the 10-year period January 1, 2000 to 
December 31, 2009.3 Data from a subset of 40,124 deceased 
subjects, who were not donors after cardiac death (donation 
after cardiac death, DCD) and for whom complete data on 
the hormonal therapy administered (if any) were available, 
were analyzed. The data were analyzed by assessing the pro-
curement of the following organs from each donor – heart, 
lungs, kidneys, liver, pancreas, and intestines. Treatment with 
four different hormones (with the aim of improving organ 
function and increasing organ procurement) was recorded 
and analyzed – thyroid hormone (T3 or T4), a corticosteroid, 
antidiuretic hormone (arginine vasopressin or DDAVP), 
and insulin. An individual donor could have received one 
or more (or none) of these four hormones. For convenience 
of  illustration, the hormonal treatment modalities are 
categorized by thyroid hormone in Table 1.
Analytical methods
The transplantation rate was calculated to evaluate the 
efficacy of the hormonal replacement regimen on organ 
procurement (and subsequent successful transplantation). 
The successful transplantation rate for a specific organ given 
a specific hormonal treatment modality, was calculated as 
the number of organs procured/transplanted divided by all 
of the organ dispositions among the donors in that modality 
group. The data management and analysis were performed 
using SAS (v9.3; SAS Inc., Cary, NC, USA). Missing values 
were excluded from the analysis.
Estimation of predicted margins
To select the best hormonal replacement modality for organ 
procurement, we used a logistic regression model to estimate 
the predicted margins or the logits for each particular organ 
type, including heart, lungs, kidneys, liver, pancreas, and 
intestine. The logits for each type of organ were estimated 
based on the following model, which adjusted for age, sex, 
and body mass index (BMI):
log ( )it p n
p
p
HR age
sex BMI
=
-




= + ⋅ + ⋅
+ ⋅ + ⋅
1
1 0 1 2
3 4
β β β
β β  (1)
where p is the probability of successfully procuring/trans-
planting an organ given a specific hormonal replacement 
regimen.
Furthermore, we selected the optimal hormonal replace-
ment regimen for multiple organ procurement (intestine not 
included in the analysis) by constructing a generalized linear 
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mixed model to estimate least square means or LS-means, 
defined as follows:
g E Y HR age
sex BMI organ
( [ | ])γ β β β
β β γ
= + ⋅ + ⋅
+ ⋅ + ⋅ + ⋅ ⋅
0 1 2
3 4  (2)
where β
s
 are the fixed effects and γ is the random effect. Four 
variance–covariance structures were used to estimate the 
random effect, ie, variance component (VC), compound sym-
metry (CS), autoregressive (AR), and unstructured (UN).
Table 2 organ transplantation rates
Organs BDOD  
transplanted
Total  
BDOD
Success 
rate (%)
heart 12,461 40,124 31.06
lungs 7,414 40,124 18.48
liver 32,103 39,643a 80.98
Kidneys 30,670 40,124 76.44
Pancreas 7,595 40,121b 18.93
Intestines 997 40,120c 2.49
Notes: When information on the ultimate disposition of the procured organ was 
missing, the data were excluded: a481 donors were excluded from the analysis; b3 
donors were excluded; c4 donors excluded.
Abbreviation: Bdod, brain-dead organ donors.
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Figure 1 Predicted margins of the logits or lS-means estimated from each logistic regression model based on the successful procurement/transplantation rates for each 
organ across hormonal replacement regimen groups.
Abbreviation: lS, least square.
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Multiple comparison procedures
To select the optimal modality for single and multiple 
organ procurement, multiple comparison procedures 
(MCA, MCC, and MCB) were applied based on the 
logits from either the logistic regressions or general-
ized linear mixed models (GLMM). Let θ
1
, θ
2
, …, θ
k
 
denote the treatment effect of logits estimated from 
the models described above. In the MCA model, the 
parameters of interest were θ
i
 – θ
j
 for all i ≠ j, and there 
were k(k – 1)/2 or 120 pair-wise  comparisons. In the 
MCC model, the hormonal replacement modality with 
the highest value was used as the control and denoted 
as  treatment c. Then the parameters of interest were 
δ
i
 = θ
i
 – θ
c
 for i = 1, 2, …, k–1, which in this study involved 
15 comparisons. Similar to the MCC, the parameters of 
interest for the MCB were the difference between each 
hormonal replacement modality and the true best of the 
 others. For a specific hormonal replacement modality i 
with an unknown real value θ
i
, the ordered kth treatment 
effect was θ
[k]
 = max
1#i#k
θ
i
. If modality i is preferred to 
modality j when θ
i
 . θ
j
, the parameters δ
i
 = θ
[k]
 – θ
i
 reflect 
inversely the success of each treatment relative to the best 
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Figure 2 Dunnett’s MCC simultaneous confidence intervals for the differences of the LS-means estimated from each logistic regression model using multiple comparisons 
with the highest lS-mean across hormonal replacement regimen groups.
Abbreviations: lS, least square; MCC, multiple comparisons with control; Udl, upper decision limit; ldl, lower decision limit.
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treatment for i = 1, 2, …, k. The simultaneous confidence 
intervals on the parameters of  interest for the multiple 
comparison procedures were constructed to assess efficacy 
for each hormonal modality for individual and multiple 
organ procurement. The Tukey MCA procedure was used 
for all pair-wise comparisons,13 and the Dunnett–Hsu MCC 
and the Hsu MCB procedures were used to select the best 
modality based on the largest mean logits or LS-means.
Results
The best hormonal replacement modality selection was 
based on single organ type procurement and multiple organ 
procurement, including the average number of multiple organ 
procurements for each individual brain-dead organ donor.
general information on organ 
procurements
For each brain-dead potential organ donor, there were six 
specific organs that could be procured (and transplanted). 
Table 2 lists the overall success rates for each organ type 
procured (and transplanted) without specifying the hor-
monal replacement information. Procurement of the liver 
or kidneys had higher success rates (80.98% and 76.44%, 
respectively) than that of heart, pancreas, or lungs (31.06%, 
A1
A2
A3
A4
A5
A6
A7
A8
B1
B2
B3
B4
B5
B6
B7
B8
A1
A2
A3
A4
A5
A6
A7
A8
B1
B2
B3
B4
B5
B6
B7
B8
A1
A2
A3
A4
A5
A6
A7
A8
B1
B2
B3
B4
B5
B6
B7
B8
A1
A2
A3
A4
A5
A6
A7
A8
B1
B2
B3
B4
B5
B6
B7
B8
A1
−2 −1.5 −1 −0.5 0 0.5
−2 −1.5 −1 −0.5 0 0.5
−2 −1.5 −1
−1
−0.5
−0.5
0
0
0.5
0.5
−1.5 −1 −0.5 0 0.5
−2.5 −2 −0.5−1.5 −1
MCB 95% CI (intestines)
G
ro
u
p
s
G
ro
u
p
s
G
ro
u
p
s
G
ro
u
p
s
G
ro
u
p
s
G
ro
u
p
s
MCB 95% CI (kidneys)
MCB 95% CI (lungs)MCB 95% CI (heart)
MCB 95% CI (liver)
MCB 95% CI (pancreas)
0 0.5
A2
A3
A4
A5
A6
A7
A8
B1
B2
B3
B4
B5
B6
B7
B8
A1
A2
A3
A4
A5
A6
A7
A8
B1
B2
B3
B4
B5
B6
B7
B8
Figure 3 hsu’s MCB simultaneous CIs for the differences of the lS-means estimated from each logistic regression model using multiple comparisons with the best lS-mean 
across hormonal replacement regimen groups.
Abbreviations: CI, confidence interval; LS, least square; MCB, multiple comparisons with the best.
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18.93%, and 18.48%, respectively). Procurement of intestines 
had the lowest success rate (2.49%), but this was almost cer-
tainly related to the reduced need for intestinal transplantation 
compared with transplantation of other vital organs.
the optimal hormonal replacement 
regimen based on individual organ 
procurement
Generally, multiple organs are procured from each donor. 
In order to assess whether a certain hormonal replacement 
modality proved beneficial for a specific organ, but not for 
others, we determined the optimal modality for each specific 
organ, eg, the heart. Figure 1 shows predicted margins or 
LS-means estimated from logistic regressions based on the 
success rates for procurement of different organs across the 
16 hormonal treatment categories, ie, 15 hormonal treat-
ment modalities and one in which no hormonal therapy 
was administered. The largest LS-mean of the modalities 
was identified for each organ type. The effects of hormonal 
replacement therapy were reflected by the values of the 
predicted population margins or LS-means. The higher the 
value, the better the effect. The simultaneous confidence 
intervals for LS-mean differences between each modality 
and the modality with the largest LS-mean value are shown 
in Figure 2.
When the Dunnett procedure was used, the best hormonal 
replacement modalities for procurement of heart, lungs, 
liver, kidneys, pancreas, and intestines were A4, A1, B2, 
A1, A2, and A2, respectively. However, the best modality A4 
for heart procurement was not significantly better than A1, 
A2, and A3. Similarly, A1 was not significantly better than 
A4 for kidneys procurement, and A2 was not significantly 
better than A4 for intestine procurement (Figure 2). When 
the Hsu MCB procedure was used, the best modalities for 
heart, lungs, liver, kidneys, pancreas, and intestines were A4, 
A1, B2, A1, A2, and A2, respectively. As shown in Figure 3, 
the results were similar to those when the Dunnett MCC 
procedure was used; where the optimal hormonal therapy, 
A4, was not significantly better than A1, A2, and A3 for 
heart procurement, A1 was not significantly better than A4 
for kidneys procurement, and A2 was not significantly better 
than A4 for intestine procurement.
the optimal hormonal replacement 
regimen based on multiple organ 
procurement
There were two parameters used for selection of the best 
modality for multiple organ procurement/transplantation, ie, 
average number of organs procured from an individual donor 
and the success rate for multiple organ procurement.
This approach was based on the LS-means estimated from 
the GLMM using four covariance structures for estimating 
the random effect. As shown in Table 3, though there were 
slight LS-mean value differences among these four covari-
ance structure models, there were no differences in terms of 
the ranks of the hormonal replacement effect, and group A1 
was the top rank of all four models. Pair-wise comparisons 
were performed using the Tukey–Kramer procedure. The 
Table 3 lS-means estimated from different covariance structure models
Group Covariance structure
Compound  
symmetry
Autoregressive Variance  
components
Unstructured
A1 0.091 -0.012 0.091 -0.500
A2 0.081 -0.022 0.081 -0.509
A3 -0.011 -0.114 -0.011 -0.602
A4 -0.009 -0.112 -0.009 -0.600
A5 -0.430 -0.533 -0.430 -1.020
A6 -0.291 -0.394 -0.291 -0.881
A7 -0.476 -0.579 -0.476 -1.067
A8 -0.526 -0.628 -0.526 -1.116
B1 -0.171 -0.274 -0.171 -0.762
B2 -0.054 -0.157 -0.054 -0.645
B3 -0.472 -0.575 -0.472 -1.063
B4 -0.389 -0.492 -0.389 -0.980
B5 -0.686 -0.789 -0.686 -1.276
B6 -0.681 -0.784 -0.681 -1.272
B7 -0.981 -1.084 -0.981 -1.571
B8 -0.813 -0.916 -0.813 -1.403
Abbreviation: lS, least square.
Clinical Epidemiology 2015:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
23
hormonal therapy for brain-dead organ donors
results showed that group A1 was the best modality; however, 
it was not significantly better than many other groups, such 
as A2, A3, and A4, after the Tukey–Kramer adjustment 
(Figure 4).
When the Dunnett–Hsu procedure was used to construct 
the simultaneous confidence intervals or 95% decision limits, 
the results were similar to those when pair-wise comparisons 
were performed. A1 was the best modality for multiple organ 
procurement (Figure 5), but was not significantly better than 
A2 and A4.
Group A1 was also identified as the best treatment 
modality using the average number of organs procured 
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Figure 4 Pair-wise confidence intervals from generalized linear mixed models with four different covariance structures using the Tukey–Kramer procedure across hormonal 
replacement regimen groups.
Abbreviations: AR, autoregressive; CS, compound symmetry; UN, unstructured; VC, variance component.
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for each donor based on the general linear models with 
or without adjusting the covariates, age, sex, and BMI. As 
shown in Figure 6, group A1 was the best modality using 
both Dunnett–Hsu MCC and Hsu MCB procedures. How-
ever, without the covariate adjustment, group A1 was not 
significantly better than A2, A3, or A4 when the MCC was 
used, and similar results were observed when the MCB was 
used, whereas, after the covariate adjustment, A1 was the best 
modality when MCC was used, but A1 was not significantly 
better than A2, A3, or A4 when the MCB was used.
The detailed hormonal replacement combinations 
for each organ type and multiple organ procurement are 
 summarized in Table 4.
Discussion
Hormonal replacement therapy has been widely used to 
increase organ procurement from human brain-dead donors. 
To date, there has been no conclusive research indicating the 
optimal hormonal combinations for procurement of a specific 
type of organ or of multiple organs. In the present study, we 
proposed a two-step approach using generalized linear mod-
els (GLM) or GLMM, and multiple comparison procedures. 
Using Tukey’s MCA, Dunnett–Hsu’s MCC, and Hsu’s MCB, 
we analyzed data from 40,124 brain-dead potential donors 
(in which definitive hormonal replacement therapy was docu-
mented) with the aim of identifying the optimal therapy for 
both individual and multiple organ procurement.
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Abbreviations: AR, autoregressive; CS, compound symmetry; ldl, lower decision limit; lS, least square; Udl, upper decision limit; UN, unstructured; VC, variance 
component.
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Figure 6 LS-means and the simultaneous confidence intervals for the differences from generalized linear model based on the average number of organs procured from each 
donor using the dunnett–hsu MCC procedure (upper panels) and the hsu MCB procedure (lower panels) across hormonal replacement regimen groups.
Note: the right panels were based on the models adjusted for age, sex, and BMI.
Abbreviations: BMI, body mass index; CI, confidence interval; LDL, lower decision limit; LS, least square; MCB, multiple comparisons with the best; MCC, multiple 
comparisons with control; Numorg, number of organs; Udl, upper decision limit.
We determined that thyroid hormone (T3 or T4), 
a corticosteroid, and antidiuretic hormone played important 
roles in the management of the donor if organ procurement 
(and transplantation) was to be maximized. Although there 
was some variation in the optimal combination of hormones 
for a specific organ, the combination of thyroid hormone, 
a corticosteroid, antidiuretic hormone, and insulin was the 
optimal hormonal therapy to maximize multiple organ pro-
curement. Insulin played a relatively minor role, and might 
even be detrimental to procurement of the pancreas.3
To select the best modality, we applied multiple com-
parison methods to control type I error rates. Tukey’s MCA 
is the most powerful test when performing all pair-wise 
comparisons and Dunnett’s MCC is the most powerful test 
when comparing to a “control”; whereas Hsu’s MCB is the 
most powerful test when not requiring all pair-wise com-
parisons, which compares between each sample mean and 
the “best” of all the other means, where one specifies that 
“best” means either largest or smallest. It is a modification of 
Dunnett’s MCC method by treating the “best” as an unknown 
parameter. The purpose is to select which group(s) is/are 
the best, ie, not significantly different from each other, but 
significantly better than the others. In this data analysis, we 
yielded similar results using the three methods because of 
the large sample size. We applied the Dunnett–Hsu MCC by 
treating the highest value by treatment effect as the “control” 
group, and testing whether the other treatment effects were 
inferior to the “control”, which then we considered as the 
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Table 4 optimal hormonal replacement modalities to maximize 
organ transplantation
Organ transplanted Hormonal replacement modality 
(group)
heart t3/t4 + Adh (A4), t3/t4 + I + Adh (A3),  
t3/t4 + C + Adh (A2), 
t3/t4 + C + I + Adh (A1)
lungs t3/t4 + C + I + Adh (A1)
liver C + Adh (B2)
Kidneys t3/t4 + C + I + Adh (A1), t3/t4 + Adh (A4)
Pancreas t3/t4 + C + Adh (A2)
Intestines t3/t4 + C + Adh (A2), t3/t4 + Adh (A4)
Multiple organs 
(intestines not included)
t3/t4 + C + I + Adh (A1), t3/t4 + C + Adh 
(A2), t3/t4 + Adh (A4)
Abbreviations: Adh, antidiuretic hormone (ddAVP or arginine vasopressin); 
C, corticosteroid; I, insulin; t3/t4 = thyroid hormone (triiodothyronine [t3] or 
levothyroxine [t4]).
best modality, as a comparison with the results from the Hsu 
MCB. The best hormonal replacement selections were based 
on the simultaneous confidence intervals using both MCC 
and MCB procedures since Tukey’s MCA is too conservative 
in the optimal treatment selection.
There are several limitations to our study, most of which 
were unavoidable. For example, the study was retrospective, 
and the UNOS database is largely unaudited and may contain 
minor inaccuracies. The reasons why an organ may not have 
been procured were not known to us though, in a study of 
such a large number of potential donors, this factor should 
not have played a significant role. It was also unknown to 
us whether hormonal therapy was administered as part of 
a routine protocol or because the donor’s hemodynamic 
status was deteriorating. Antidiuretic hormone is adminis-
tered to any donor with diabetes insipidus, which is almost 
ubiquitous after brain death, whereas T3/T4 may only be 
given when hemodynamic status is poor. Data on inotropic 
support and the dosage of the hormones administered were 
not uniformly recorded. It was also uncertain to us whether 
the donor organs had been affected by such factors as a 
period of cardiac arrest or previous cocaine use. Neverthe-
less, though a prospective randomized study would carry 
greater scientific value, we believe the current retrospective 
analysis has sufficient statistical power to allow conclusions 
to be drawn.
Certain questions are raised by our results. For 
example, why was procurement of livers not increased by 
thyroid hormonal therapy? We have attempted to address 
this point elsewhere.14 In brief, we note that livers were 
procured from a significantly greater number of donors 
(.80%) than any other organ (if a pair of kidneys or lungs 
is considered as a single organ) (P,0.0001) irrespective 
of the hormonal treatment that the donor received. This 
suggests that the liver (even when the donor is untreated) 
is perhaps more resistant to brain death–associated injury 
than other organs, as it may have a greater adaptability 
to chemical, nutritional, and immunogenic stimuli than 
other vital organs. However, we remain uncertain why 
corticosteroids did not appear always beneficial to pro-
curement of the heart, but this may possibly be related to 
the fact that T3/T4 is particularly effective in increasing 
myocardial energy stores and in reducing the inflammatory 
response, which may negate the weaker effect provided 
by corticosteroids.
The present paper, however, was primarily directed at 
the statistical methods that might be optimal to determine 
the effect of the various hormones available for treatment 
of potential organ donors by appropriately controlling 
type I error. Based on the available UNOS data, and using 
the proposed best treatment selection method, we cautiously 
recommend that the combination of all four hormones is 
the optimal modality for multiple organ procurement for 
transplantation. However, our goal is to extend the method 
to improve selection of the best treatment or intervention in 
clinical and epidemiological studies.
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